Placing in-vitro heteroresistance in the context of clinical results
- PMID: 34174228
- DOI: 10.1016/S1473-3099(21)00328-5
Placing in-vitro heteroresistance in the context of clinical results
Conflict of interest statement
AKo, AKa, CL, YY, and TDN are employees of Shionogi. RE is a consultant for Shionogi and received a consultancy fee. MB has participated in advisory boards or received speaker honoraria from Angelini, Astellas, Bayer, Basilea, bioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Roche, and Shionogi, and has received study grants from Gilead, MSD, Pfizer, and Shionogi.
Comment on
- 
  
  Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.Lancet Infect Dis. 2021 May;21(5):597-598. doi: 10.1016/S1473-3099(21)00194-8. Lancet Infect Dis. 2021. PMID: 33894839 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
 
        